Massive Bio helps pre-screen patients for clinical trials, streamlining the trial enrollment process and reducing clinical staff time.

Myelofibrosis
Myelofibrosis

A phase III randomized, double-blind, placebo-controlled study in participants with Myelofibrosis

  • Phase III Study
  • Male, Female
  • Age 18+
Follicular Lymphoma/Marginal Zone Lymphoma
Follicular Lymphoma/Marginal Zone Lymphoma

A phase III randomized, double-blind, placebo-controlled, multicenter study in patients with relapsed/refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma

  • Phase III Study
  • Male, Female
  • Age 18+
Prostate Cancer
Prostate Cancer

A phase III, randomized study for patients with Stage IV Adenocarcinoma of the Pancreas with no prior treatment for metastatic disease

  • Phase III Study
  • Male
  • Age 18+
Stage IV Pancreatic Cancer
Stage IV Pancreatic Cancer

A phase III, randomized study for patients with stage IV adenocarcinoma of the pancreas with no prior treatment for metastatic disease

  • Phase III Study
  • Male, Female
  • Age 18+
HER2 Positive Solid Tumors, GE junction, Gastric Cancer
HER2 Positive Solid Tumors, GE junction, Gastric Cancer

A Phase I/II, open-label, multicenter study in patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer

  • Phase I/II Study
  • Male, Female
  • Age 18+
Alteration/Biomarker-Positive Solid Tumors
Alteration/Biomarker-Positive Solid Tumors

A Phase II study in patients with Alteration/Biomarker-Positive Advanced or Metastatic Solid Tumors

  • Phase II Study
  • Male, Female
  • Age 18+
Breast Cancer FGFR
Breast Cancer FGFR

A phase II, non-randomized clinical trial for patients with Metastatic Breast Cancers Harboring FGFR Amplifications

  • Phase II Study
  • Female
  • Age 18+
Cervical Cancer
Cervical Cancer

A phase II randomized study in women with Recurrent/Persistent/Metastatic Cervical Cancer who have progressed following first-line therapy

  • Phase II Study
  • Female
  • Age 18+
Follicular Lymphoma/Marginal Zone Lymphoma
Follicular Lymphoma/Marginal Zone Lymphoma

A phase III randomized, double-blind, placebo-controlled study in patients with Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma

  • Phase III Study
  • Male, Female
  • Age 18+
Mantle Cell Lymphoma
Mantle Cell Lymphoma

A phase III randomized, double-blind study for the treatment of Newly Diagnosed Mantle Cell Lymphoma

  • Phase III Study
  • Male, Female
  • Age 18+
Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

A phase 1b/2a basket study in adult patients with Relapsed/Refractory Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

  • Phase 1b/2a Study
  • Male, Female
  • Age 18+
Non-Small Cell Lung Cancer MET
Non-Small Cell Lung Cancer MET

A first-in-human/phase I/II study for patients with Non-Small Cell Lung Cancer with MET Alteration

  • FIH, Phase I/II Study
  • Male, Female
  • Age 18+

Massive Bio’s SYNERGY-AI database combines artificial intelligence, genomic biomarkers, and multi-variate analysis to accelerate clinical trial matching and promote access to promising cancer therapies. We then help facilitate enrollment into the study by providing support during the transition.

Provider Referral

Please provide your patient’s contact information, and a representative will contact them soon.

For questions, please contact us at providersupport@massivebio.com or 844-627-7246

Looking for a different trial?

Take advantage of our Clinical Trial Matching Service. Massive Bio is 4x more successful in finding cancer clinical trial matches for patients than any other service provider.